KDR and lymphoma: A trial of the vegf antibody, bevacizumab, in relapsed aggressive-histology lymphoma showed some modest activity (pr = 5% and sd = 20%), with a relationship between vegf and vegfr expression suggesting a possible autocrine pathway in some patients 20, which is consistent with preclinical models 18.